Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2010-11-19
2011-12-27
Johannsen, Diana (Department: 1634)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S006180, C702S019000, C514S301000, C536S023200, C536S023500, C546S114000
Reexamination Certificate
active
08084210
ABSTRACT:
The present invention provides methods for predicting or determining a subject's response to an antiplatelet agent, and methods for determining a subject's suitability to a treatment regime or intervention for a disease associated with platelet aggregation, using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject's response to an antiplatelet agent. Nucleotide probes and primers, kits, and microarrays suitable for such assessment are also provided.
REFERENCES:
patent: 5478723 (1995-12-01), Parkinson et al.
patent: 5912120 (1999-06-01), Goldstein et al.
patent: 5989844 (1999-11-01), Shimada et al.
patent: 6812339 (2004-11-01), Venter et al.
patent: 6884810 (2005-04-01), Nagasawa et al.
patent: 6986992 (2006-01-01), Chui et al.
patent: 7833744 (2010-11-01), Flockhart et al.
patent: 2003/0059774 (2003-03-01), Risinger et al.
patent: 2003/0103901 (2003-06-01), Leyland-Jones
patent: 2004/0084867 (2004-05-01), Leyland-Jones
patent: 2004/0199333 (2004-10-01), Hoffman et al.
patent: 2005/0191731 (2005-09-01), Judson et al.
patent: 2006/0040295 (2006-02-01), Kumar et al.
patent: 2006/0110767 (2006-05-01), Schuetz et al.
patent: 2006/0259251 (2006-11-01), Warrington
patent: 2008/0085240 (2008-04-01), Flockhart et al.
patent: 2008/0248466 (2008-10-01), Gordon et al.
patent: 2009/0087856 (2009-04-01), Caldwell et al.
patent: 2009/0099030 (2009-04-01), Merante
patent: 2009/0138286 (2009-05-01), Linder et al.
patent: 2009/0233288 (2009-09-01), Hirai et al.
patent: 2009/0269756 (2009-10-01), Majima et al.
patent: 0897015 (2000-05-01), None
patent: 02/38589 (2002-05-01), None
patent: 2002046209 (2002-06-01), None
patent: 2005038049 (2005-04-01), None
patent: 2007097884 (2007-08-01), None
patent: 2008066162 (2008-06-01), None
Sibbing, D. et al. Circulation 121:512-518 (Feb. 2010; published online Jan. 18, 2010).
Trenk, D. et al. Circulation 118(18):Suppl 2:S814-S815 (Oct. 2008).
Dahlman, I et al. Nature Genetics 30:149-150 (Feb. 2002).
Abell & Liu. “Abstract 272: In vitro Platelet Aggregation as a Biosensor for Clopidogrel Active Metabolite Formation,” Circulation. 2006;114:II—27.
Brandt et al., “Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel,” Journal of Thrombosis and Haemostasis (2007) vol. 5, Issue 12, pp. 2429-2436.
Brockimöller & Tzvetkov, “Pharmacogenetics: data, concepts and tools to improve drug discovery and drug treatment,” Eur J Clin Pharmacol. Feb. 2008;64(2):133-57. Epub Jan. 26, 2008.
Chen et al., “Inhibition of ADP-Induced Platelet Aggregation by Clopidorgrel is Related to CYP2C19 Genetic Polymorphisms,” Clin. and Exp. Pharma. and Physiol., 2008, 35:904-908.
Daniel & Edeki. “Genetic polymorphism of S-mephenytoin 4′-hydroxylation.” Psychopharmacol Bull. 1996;32 (2):219-30.
Evans & Johnson, Annual Review of Genomics and Human Genetics 2 (2001), 9-39.
Farid et al., “Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently.” Clin Pharm Ther., 2007, 81:735-741.
Fontana et al., “Biological effect of increased maintenance dose of clopidogrel in cardiovascular outpatients and influence of the cytochrome P450 2C19*2 allele on clopidogrel responsiveness,” Thromb Res. 2008;121(4):463-8. Epub Aug. 2, 2007.
Fontana et al., “Influence of CYP2C19 and CYP3A4 gene polymorphisms on clopidogrel responsiveness in healthy subjects,” J Thromb Haemost. Oct. 2007;5(10):2153-5. Epub Aug. 3, 2007.
Geisler et al. “CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation.” Pharmacogenomics. Sep. 2008;9(9):1251-9.
Goldstein & Blaisdell. “Genetic tests which identify the principal defects in CYP2C19 responsible for the polymorphism in mephenytoin metabolism.” Methods Enzymol. 1996;272:210-8.
Hahnenberger, et al., “Use of oligonucleotide array hybridization for genotyping CYP2D6 and CYP2C19,” 1997, Clinical Pharmacology and Therapeutics, 61(2):165.
Hulot et al., “Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects,” Blood 108:2244-2247, Oct. 2006.
Ingelman-Sundberg et al., “Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms,” Naunyn Schmiedebergs Arch Pharmacol. Jan. 2004;369(1):89-104. Epub Oct. 22, 2003.
Ingelman-Sundberg et al., “Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects,” Pharmacol Ther. Dec. 2007;116(3):496-526. Epub Oct. 9, 2007.
Ingelman-Sundberg et al., “Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment,” Trends Pharmacol Sci. Aug. 1999;20(8):342-9.
Kurzawski et al., “Effect of CYP2C19*17 gene variant on Helicobacter pylori eradication in peptic ulcer patients.” Eur J Clin Pharmacol. Oct. 2006;62(10):877-80. Epub Aug. 16, 2006.
Payne et al. “Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel,” Journal of Cardiovascular Pharmacology:Nov. 2007—vol. 50—Issue 5—pp. 555-562.
Rudberg et al., “Impact of the ultrarapid CYP2C19*17 allele on serum concentration of escitalopram in psychiatric patients,” Clin Pharmacol Ther. Feb. 2008;83(2):322-7. Epub Jul. 11, 2007.
Sim et al., “A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants,” 2006, Clinical Pharmacology & Therapeutics (2006) 79, 103-113.
Demorais et al., “Identification of a New Genetic Defect Responsible for the Polymorphism of (s)-Mephenytoin Metabolism in Japanese,” Molecular Pharmacology, 1994, 46:594-598.
Desta et al., “Rapid Identification of Hepatic Cytochrome P450 2C19 Activity Using a Novel and Noninvasive [13C] Pantoprazole Breath Test,” J Pharmacol. Exp. Thera., 2009, 329:297-305.
Freedman et al., “Clopidogrel, Genetics, and Drug Responsiveness,” N Eng. J. Med., 2009, 360:411-413.
Helsby, N. A., “Pheno- or Genotype for the CYP2C19 Drug Metabolism Polymorphism: the Influence of Disease,” Proc. West. Pharmacol. Soc., 2008, 51:5-10.
Mega et al., “Cytochrome P-450 Polymorphisms and Response to Clopidogrel,” N Eng J Med., 2009, 360:354-362.
Simon et al., “Genetic Determinants of Response to Clopidogrel and Cardiovascular Events,” N Eng J Med., 2009, 360:363-375.
Dahl Marja-Liisa
Gladding Patrick A.
Gunes Arzu
Webster Mark W.
Casimir Jones S.C.
Johannsen Diana
Theranostics Laboratory
LandOfFree
Methods for the assessment of drug response does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for the assessment of drug response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for the assessment of drug response will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4298640